The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
Envisaged surgical candidate for interval debulking after 2 cycles of treatment
Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures
Elevated liver enzymes (double of normal range: ASAT > 68 U/l; ALAT > 82 U/l; GGT > 80 U/l)
Elevated creatinine (double of normal range: >120 mmol/l))
ECOG ≥3
Pregnant or lactating women
Swiss GO Trial Group
Lead sponsor
Tumor Profiler Center Switzerland
Collaborator